Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve H Thorne

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|June 11, 2016
Noninvasive Imaging of Fluorescent Reporters in Small Rodent Models Using Fluorescence Molecular TomographyWeizhou Hou, Steve H Thorne
Oncolytic Virotherapy|August 12, 2016
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapyPadma Sampath, Steve H Thorne
Nature Reviews. Cancer|December 24, 2008
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerDavid H Kirn, Steve H Thorne
Expert Opinion on Biological Therapy|July 23, 2004
Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virusSteve H Thorne, David H Kirn
Theranostics|April 18, 2012
Theranostic potential of oncolytic vaccinia virusJuan J Rojas, Steve H Thorne
Science (New York, N.Y.)|March 25, 2006
Synergistic antitumor effects of immune cell-viral biotherapySteve H Thorne, Robert S Negrin, Christopher H Contag
Advances in Experimental Medicine and Biology|December 25, 2017
Oncolytic Virotherapy and the Tumor MicroenvironmentSara E Berkey, Steve H Thorne, David L Bartlett
Cancer Cell|July 5, 2016
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to ImmunotherapyWeizhou Hou, Padma Sampath, Juan J Rojas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic VirotherapyJuan J Rojas, Padma Sampath, Weizhou Hou, et al.
Current Pharmaceutical Biotechnology|July 12, 2011
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594Caroline J Breitbach, Steve H Thorne, John C Bell, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Methods in Molecular Biology (Clifton, N.J.)|June 11, 2016
Noninvasive Imaging of Fluorescent Reporters in Small Rodent Models Using Fluorescence Molecular TomographyWeizhou Hou, Steve H Thorne
Oncolytic Virotherapy|August 12, 2016
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapyPadma Sampath, Steve H Thorne
Nature Reviews. Cancer|December 24, 2008
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancerDavid H Kirn, Steve H Thorne
Expert Opinion on Biological Therapy|July 23, 2004
Future directions for the field of oncolytic virotherapy: a perspective on the use of vaccinia virusSteve H Thorne, David H Kirn
Theranostics|April 18, 2012
Theranostic potential of oncolytic vaccinia virusJuan J Rojas, Steve H Thorne
Science (New York, N.Y.)|March 25, 2006
Synergistic antitumor effects of immune cell-viral biotherapySteve H Thorne, Robert S Negrin, Christopher H Contag
Advances in Experimental Medicine and Biology|December 25, 2017
Oncolytic Virotherapy and the Tumor MicroenvironmentSara E Berkey, Steve H Thorne, David L Bartlett
Cancer Cell|July 5, 2016
Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to ImmunotherapyWeizhou Hou, Padma Sampath, Juan J Rojas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic VirotherapyJuan J Rojas, Padma Sampath, Weizhou Hou, et al.
Current Pharmaceutical Biotechnology|July 12, 2011
Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594Caroline J Breitbach, Steve H Thorne, John C Bell, et al.
Pageof 4